Hansa Biopharma Feed

2025-12-19 20:35:00 Hansa Biopharma AB: Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

2025-12-19 20:35:00 Hansa Biopharma AB: Hansa Biopharma lämnar in BLA-ansökan till FDA för imlifidase för desensitisering vid njurtransplantation

2025-12-19 11:45:00 Hansa Biopharma AB: Hansa Biopharma presenting at 44th Annual J.P. Morgan Healthcare Conference

2025-12-19 11:45:00 Hansa Biopharma AB: Hansa Biopharma presenterar på den 44:e årliga J.P. Morgan Healthcare-konferensen

2025-12-16 23:07:00 Hansa Biopharma AB: Hansa ger uppdatering om den registreringsgrundande fas 3-studien för anti-glomerulär basalmembransjukdom (anti-GBM) 27,94 SEK | -16,30% | 110 MSEK

2025-12-16 23:07:00 Hansa Biopharma AB: Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease 27,94 SEK | -16,30% | 110 MSEK

2025-12-15 07:00:00 Hansa Biopharma AB: Hansa Biopharma announce changes to strengthen European and International organisation 34,50 SEK | -3,90% | 13,0 MSEK

2025-12-15 07:00:00 Hansa Biopharma AB: Hansa Biopharma gör förändringar för att stärka den europeiska och internationella organisationen 34,50 SEK | -3,90% | 13,0 MSEK

2025-11-13 15:00:00 Hansa Biopharma AB: Hansa Biopharma presenterar vid Jefferies Global Healthcare Conference och DNB Carnegie's 16th Annual Nordic Healthcare Conference 26,96 SEK | +1,58% | 17,4 MSEK

2025-11-13 15:00:00 Hansa Biopharma AB: Hansa Biopharma presenting at Jefferies Global Healthcare Conference and DNB Carnegie's 16th Annual Nordic Healthcare Conference 26,96 SEK | +1,58% | 17,4 MSEK

2025-11-12 08:00:00 Hansa Biopharma AB: Kommande KOL-samtal idag: Insikter om klinisk praxis och fas 3- resultaten med imlifidase 26,54 SEK | +0,68% | 15,9 MSEK

2025-11-12 08:00:00 Hansa Biopharma AB: Upcoming KOL Call today: Insights on clinical practice and imlifidase Phase 3 Results 26,54 SEK | +0,68% | 15,9 MSEK

2025-11-05 11:00:00 Hansa Biopharma AB: Hansa at Truist Securities, Stifel, and SEB Healthcare conferences 29,42 SEK | -3,22% | 21,4 MSEK

2025-11-05 11:00:00 Hansa Biopharma AB: Hansa deltar vid konferenserna Truist Securities, Stifel och SEB Healthcare 29,42 SEK | -3,22% | 21,4 MSEK

2025-10-31 12:00:00 Hansa Biopharma AB: Hansa Biopharma: Ökning av antalet aktier och röster 31,20 SEK | +1,76% | 14,3 MSEK

2025-10-31 12:00:00 Hansa Biopharma AB: Hansa Biopharma: Increase in number of shares and votes 31,20 SEK | +1,76% | 14,3 MSEK

2025-10-30 07:00:00 Hansa Biopharma AB: Hansa Biopharma redovisar finansiella resultat för tredje kvartalet och delårsperioden 2025 30,66 SEK | -11,03% | 95,5 MSEK

2025-10-30 07:00:00 Hansa Biopharma AB: Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results 30,66 SEK | -11,03% | 95,5 MSEK

2025-10-29 18:00:00 Hansa Biopharma AB: Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results 30,66 SEK | -11,03% | 95,5 MSEK

2025-10-29 18:00:00 Hansa Biopharma AB: Hansa arrangerar webcast med framstående transplantationskirurger: Insikter om klinisk praxis och fas 3- resultaten med imlifidase 30,66 SEK | -11,03% | 95,5 MSEK

2025-10-10 10:00:00 Hansa Biopharma AB: Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler-Najjar syndrome who are immune to AAV 38,60 SEK | -1,53% | 34,9 MSEK

2025-10-10 10:00:00 Hansa Biopharma AB: Data från GNT-018-IDES-studien visar att imlifidase kan användas som förbehandling till genterapi för patienter med Criegler Najjars Syndrom och som har antikroppar mot AAV 38,60 SEK | -1,53% | 34,9 MSEK

2025-10-08 16:00:00 Hansa Biopharma AB: Hansa Biopharma to host Q3 2025 interim results conference call 40,20 SEK | +2,81% | 35,5 MSEK

2025-10-08 16:00:00 Hansa Biopharma AB: Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q3 2025 40,20 SEK | +2,81% | 35,5 MSEK

2025-10-07 17:00:00 Hansa Biopharma AB: Hansa Biopharma participating in Optimum's 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025 39,10 SEK | +0,57% | 28,4 MSEK

2025-10-07 17:00:00 Hansa Biopharma AB: Hansa Biopharma deltar i Optimums 17:e årliga Healthcare Investor Conference och Nordic Life Science Days 2025 39,10 SEK | +0,57% | 28,4 MSEK

2025-10-02 08:30:00 Hansa Biopharma AB: Hansa Biopharma publishes disclosure document for admission to trading of shares on Nasdaq Stockholm 39,98 SEK | -6,46% | 82,8 MSEK

2025-10-02 08:30:00 Hansa Biopharma AB: Hansa Biopharma publicerar informationsdokument för upptagande till handel av aktier på Nasdaq Stockholm 39,98 SEK | -6,46% | 82,8 MSEK

2025-10-02 00:15:00 Hansa Biopharma AB: Hansa Biopharma has carried out a directed share issue of 17 million shares, raising proceeds of approximately USD 71 million 42,74 SEK | +8,31% | 34,8 MSEK

2025-10-02 00:15:00 Hansa Biopharma AB: Hansa Biopharma har genomfört en riktad emission av 17 miljoner aktier, vilket tillför bolaget cirka 71 miljoner USD 42,74 SEK | +8,31% | 34,8 MSEK

2025-10-01 17:31:00 Hansa Biopharma AB: Hansa Biopharma intends to carry out a directed share issue of approximately USD 60 million 39,98 SEK | -6,46% | 82,8 MSEK

2025-10-01 17:31:00 Hansa Biopharma AB: Hansa Biopharma avser genomföra en riktad nyemission om cirka 60 miljoner USD 39,98 SEK | -6,46% | 82,8 MSEK

2025-09-26 18:50:00 Hansa Biopharma AB: Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 at ESGCT congress 2025

2025-09-24 18:21:00 Hansa Biopharma AB: Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation 36,82 SEK | +11,17% | 201 MSEK

2025-09-24 18:21:00 Hansa Biopharma AB: Imlifidase når framgångsrikt primärt effektmått i den registreringsgrundande fas 3-studien ConfIdeS i USA för njurtransplantation 36,82 SEK | +11,17% | 201 MSEK

2025-09-15 16:45:00 Hansa Biopharma AB: Hansa Biopharma Presenting at the Pareto 16 Annual Healthcare Conference 29,50 SEK | +0,82% | 7,94 MSEK

2025-09-04 07:00:00 Hansa Biopharma AB: Hansa Biopharma to Participate in H.C. Wainwright 27th Annual Global Investment Conference 30,80 SEK | -4,88% | 13,0 MSEK

2025-09-02 17:30:00 Kommuniké från extra bolagsstämma i Hansa Biopharma AB (publ) 32,38 SEK | -1,34% | 7,42 MSEK

2025-09-02 17:30:00 Bulletin from the Extraordinary General Meeting in Hansa Biopharma AB (publ) 32,38 SEK | -1,34% | 7,42 MSEK

2025-08-07 07:00:00 Kallelse till extra bolagsstämma i Hansa Biopharma AB (publ) 30,40 SEK | +1,20% | 19,9 MSEK

2025-08-07 07:00:00 Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) 30,40 SEK | +1,20% | 19,9 MSEK

2025-08-01 21:15:00 Hansa Biopharma AB: Hansa Biopharma announces supportive data from treatment with imlifidase prior to the administration of gene therapy for Duchenne muscular dystrophy

2025-08-01 21:15:00 Hansa Biopharma AB: Hansa Biopharma tillkännager bekräftande resultat från behandling med imlifidase innan genterapibehandling för Duchennes muskeldystrofi

2025-07-29 18:00:00 Hansa Biopharma AB: Hansa Biopharma announces key executive appointments to support continued growth 29,00 SEK | +2,91% | 31,2 MSEK

2025-07-17 07:00:00 Hansa Biopharma AB: Hansa Biopharma redovisar resultat för andra kvartalet och delårsperioden januari-juni 2025 27,90 SEK | +7,56% | 19,6 MSEK

2025-07-17 07:00:00 Hansa Biopharma AB: Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results 27,90 SEK | +7,56% | 19,6 MSEK

2025-07-08 08:00:00 Hansa Biopharma AB: Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer 26,76 SEK | -1,11% | 7,98 MSEK

2025-07-03 08:00:00 Hansa Biopharma AB: Hansa Biopharma to host Q2 2025 interim results conference call 26,26 SEK | -0,23% | 6,06 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Hansa Biopharma

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden